NEW YORK, Jan 7, 2026, 07:47 ET — Premarket
- Tempus AI shares down about 1% in premarket after a 7.5% rise on Tuesday
- Company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12
- SEC filing shows director Jennifer Doudna sold 1,250 shares under a 10b5-1 plan
Tempus AI, Inc shares were down about 1% in premarket trading on Wednesday, easing after the Nasdaq-listed health-tech stock jumped 7.5% in the previous session. The shares last traded around $68.85, after closing at $69.54 on Tuesday. 1
The pullback comes as investors position for Tempus’ appearance at the annual J.P. Morgan Healthcare Conference, a closely watched investor meeting that often sets the tone for healthcare stocks early in the year.
Tempus said its founder and CEO Eric Lefkofsky will deliver a presentation and take questions on Jan. 12, with a live webcast available to investors. 2
Tempus has not confirmed its next earnings date, but market schedules estimate the company will report around Feb. 23. Any color on testing demand, reimbursement and spending at the conference could shape expectations heading into that report. 3
A regulatory filing showed director Jennifer Doudna sold 1,250 shares at $60.17 on Jan. 2 under a Rule 10b5-1 plan, a pre-arranged trading program that sets conditions for future stock sales. She held 22,702 shares after the sale, the filing showed. 4
Tempus last reported third-quarter revenue up 84.7% to $334.2 million and adjusted EBITDA of $1.5 million. It posted a net loss of $80.0 million and ended the quarter with $764.3 million in cash and marketable securities; Lefkofsky called positive adjusted EBITDA “an important milestone.” 5
Broader markets were cautious early Wednesday, with U.S. stock futures edging lower after a rally that pushed the S&P 500 and Dow to record closes, while investors awaited labor market data due later in the day. 6
But Tempus remains a high-beta healthcare name, and the stock can turn quickly if management offers little new at conferences or if spending rises faster than revenue growth. Any disappointment on margins or demand could test the durability of Tuesday’s sharp move.
